PCG
BMRN icon

Private Capital Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Private Capital Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-17
Closed -$1K – 2086
2021
Q3 		$1K Sell
17
-12
-41% -$947 ﹤0.01% 1964
2021
Q2 		$2K Sell
29
-20
-41% -$1.58K ﹤0.01% 1816
2021
Q1 		$4K Sell
49
-34
-41% -$2.78K ﹤0.01% 1558
2020
Q4 		$7K Sell
83
-12
-13% -$951 ﹤0.01% 1473
2020
Q3 		$7K Buy
95
+8
+9% +$809 ﹤0.01% 1414
2020
Q2 		$11K Sell
87
-8
-8% -$795 ﹤0.01% 1304
2020
Q1 		$8K Buy
95
+27
+40% +$2.33K ﹤0.01% 1335
2019
Q4 		$5K Sell
68
-63
-48% -$4.76K ﹤0.01% 1486
2019
Q3 		$9K Buy
131
+63
+93% +$4.85K ﹤0.01% 1488
2019
Q2 		$6K Sell
68
-13
-16% -$1.11K ﹤0.01% 1575
2019
Q1 		$7K Buy
81
+1
+1% +$93 ﹤0.01% 1560
2018
Q4 		$7K Buy
80
+12
+18% +$1.14K ﹤0.01% 1510
2018
Q3 		$6K Hold
68
– – ﹤0.01% 1633
2018
Q2 		$6K Buy
68
+25
+58% +$2.19K ﹤0.01% 1594
2018
Q1 		$3K Sell
43
-2,457
-98% -$211K ﹤0.01% 1734
2017
Q4 		$16 Buy
+2,500
New +$217K ﹤0.01% 1156

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Private Capital Group's BMRN Position: Q4 2021 in Review

Private Capital Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 17 shares — an estimated $1K sold.

Private Capital Group first reported a position in BMRN in Q4 2017 and held it in 16 quarters. The position peaked at $11K in Q2 2020. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

  • Private Capital Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Private Capital Group sold 17 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Private Capital Group first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 16 quarters.
  • Private Capital Group's BioMarin Pharmaceuticals position peaked at $11K in Q2 2020.
  • 556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Private Capital Group's 13F filing for Q4 2021, filed 24 Jan 2022.